The development of orally administrable gemcitabine prodrugs with d-enantiomer amino acids: Enhanced membrane permeability and enzymatic stability

European Journal of Pharmaceutics and Biopharmaceutics - Tập 86 - Trang 514-523 - 2014
Yasuhiro Tsume1, Tuba Incecayir2, Xueqin Song3, John M. Hilfinger4, Gordon L. Amidon1
1Department of Pharmaceutical Science, University of Michigan, Ann Arbor, MI, USA
2Department of Pharmaceutical Technology, Gazi University, Etiler-Ankara, Turkey
3Hospira Inc., Lake Forest, IL, USA
4TSRL, Inc., Ann Arbor, MI, USA

Tài liệu tham khảo

van Moorsel, 1997, Gemcitabine: future prospects of single-agent and combination studies, Oncologist, 2, 127, 10.1634/theoncologist.2-3-127

Zhang, 2013, Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy, Biomaterials, 34, 3447, 10.1016/j.biomaterials.2013.01.063

Han, 1998, 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter, Pharm. Res., 15, 1154, 10.1023/A:1011919319810

Han, 1998, Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter, Pharm. Res., 15, 1382, 10.1023/A:1011945420235

Song, 2005, Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport, Mol. Pharm., 2, 157, 10.1021/mp049888e

Song, 2005, Amino acid ester prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1-(beta-d-ribofuranosyl)benzimidazole as potential substrates of hPEPT1 transporter, J. Med. Chem., 48, 1274, 10.1021/jm049450i

Talluri, 2008, Synthesis, metabolism and cellular permeability of enzymatically stable dipeptide prodrugs of acyclovir, Int. J. Pharm., 361, 118, 10.1016/j.ijpharm.2008.05.024

Tolle-Sander, 2004, Increased acyclovir oral bioavailability via a bile acid conjugate, Mol. Pharm., 1, 40, 10.1021/mp034010t

Tsume, 2008, Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability, Mol. Pharm., 5, 717, 10.1021/mp800008c

Tsume, 2008, Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters, Molecules, 13, 1441, 10.3390/molecules13071441

Vig, 2003, Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis, Pharm. Res., 20, 1381, 10.1023/A:1025745824632

Kawaguchi, 1985, Specificity of esterases and structure of prodrug esters. II. Hydrolytic regeneration behavior of 5-fluoro-2′-deoxyuridine (FUdR) from 3′,5′-diesters of FUdR with rat tissue homogenates and plasma in relation to their antitumor activity, Chem. Pharm. Bull. (Tokyo), 33, 1652, 10.1248/cpb.33.1652

Landowski, 2005, Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism, Pharm. Res., 22, 1510, 10.1007/s11095-005-6156-9

Landowski, 2005, Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs, Mol. Cancer Ther., 4, 659, 10.1158/1535-7163.MCT-04-0290

Nishizawa, 1965, 3′,5′-Diesters of 5-fluoro-2′-deoxyuridine: synthesis and biological activity, Biochem. Pharmacol., 14, 1605, 10.1016/0006-2952(65)90015-8

Anand, 2003, Interactions of the dipeptide ester prodrugs of acyclovir with the intestinal oligopeptide transporter: competitive inhibition of glycylsarcosine transport in human intestinal cell line-Caco-2, J. Pharmacol. Exp. Therap., 304, 781, 10.1124/jpet.102.044313

Friedrichsen, 2002, Synthesis of analogs of l-valacyclovir and determination of their substrate activity for the oligopeptide transporter in Caco-2 cells, Eur. J. Pharm. Sci., 16, 1, 10.1016/S0928-0987(02)00047-7

Guo, 1999, Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line, J. Pharmacol. Exp. Therap., 289, 448

Hatanaka, 2004, Transport of amino acid-based prodrugs by the Na+- and Cl(−)-coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery, J. Pharmacol. Exp. Therap., 308, 1138, 10.1124/jpet.103.057109

Phan, 2003, Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor, Antimicrob. Agents Chemother., 47, 2351, 10.1128/AAC.47.7.2351-2353.2003

Umapathy, 2004, Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+), Pharm. Res., 21, 1303, 10.1023/B:PHAM.0000033019.49737.28

Anand, 2004, Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism, J. Pharmacol. Exp. Therap., 311, 659, 10.1124/jpet.104.069997

Meredith, 2000, Modified amino acids and peptides as substrates for the intestinal peptide transporter PepT1, Eur. J. Biochem., 267, 3723, 10.1046/j.1432-1327.2000.01405.x

Nielsen, 2001, Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity for and transport via hPepT1 in the human intestinal Caco-2 cell line, J. Control. Release, 76, 129, 10.1016/S0168-3659(01)00427-8

Satake, 2002, Transepithelial transport of the bioactive tripeptide, Val-Pro-Pro, in human intestinal Caco-2 cell monolayers, Biosci. Biotechnol. Biochem., 66, 378, 10.1271/bbb.66.378

Surendran, 1999, Evidence for overlapping substrate specificity between large neutral amino acid (LNAA) and dipeptide (hPEPT1) transporters for PD 158473, an NMDA antagonist, Pharm. Res., 16, 391, 10.1023/A:1018821718340

Wenzel, 1996, Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells, J. Pharmacol. Exp. Therap., 277, 831

Wenzel, 1995, Stereoselective uptake of beta-lactam antibiotics by the intestinal peptide transporter, Br. J. Pharmacol., 116, 3021, 10.1111/j.1476-5381.1995.tb15958.x

Rubio-Aliaga, 2002, Mammalian peptide transporters as targets for drug delivery, Trends Pharmacol. Sci., 23, 434, 10.1016/S0165-6147(02)02072-2

Tsume, 2011, Potential of amino acid/dipeptide monoester prodrugs of floxuridine in facilitating enhanced delivery of active drug to interior sites of tumors: a two-tier monolayer in vitro study, Pharm. Res., 28, 2575, 10.1007/s11095-011-0485-7

Gonzalez, 1998, An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2, Cancer Res., 58, 519

Garcia-Manteiga, 2003, Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine- induced cytotoxicity, Clin. Cancer Res.: An Off. J. Am. Assoc. Cancer Res., 9, 5000

Grem, 2000, 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development, Invest. New Drugs, 18, 299, 10.1023/A:1006416410198

Kahramanogullari, 2012, Algorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacy, PLoS ONE, 7, e50176, 10.1371/journal.pone.0050176

Veltkamp, 2008, New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′-difluorodeoxyuridine, Mol. Cancer Ther., 7, 2415, 10.1158/1535-7163.MCT-08-0137

O’Neill, 2002, Oral cancer treatment: developments in chemotherapy and beyond, Br. J. Cancer, 87, 933, 10.1038/sj.bjc.6600591

Stuurman, 2013, Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement, Clin. Pharmacokinet., 52, 399, 10.1007/s40262-013-0040-2

Birnie, 1963, Studies of fluorinated pyrimidines. Xviii. The degradation of 5-fluoro-2′-deoxyuridine and related compounds by nucleoside phosphorylase, Biochemistry, 2, 566, 10.1021/bi00903a031

Bonastre, 2012, Metastatic breast cancer: we do need primary cost data, Breast, 21, 384, 10.1016/j.breast.2012.03.012

Incecayir, 2013, Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification, Mol. Pharm., 10.1021/mp300410n

Tsume, 2011, The achievement of mass balance by simultaneous quantification of floxuridine prodrug, floxuridine, 5-fluorouracil, 5-dihydrouracil, alpha-fluoro-beta-ureidopropionate, alpha-fluoro-beta-alanine using LC–MS, J. Chromatogr. B: Anal. Technol. Biomed. Life Sci., 879, 915, 10.1016/j.jchromb.2011.02.045

Anand, 2002, Current prodrug strategies via membrane transporters/receptors, Expert Opin. Biol. Ther., 2, 607, 10.1517/14712598.2.6.607

Ganapathy, 1998, Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2, Biochem. Biophys. Res. Commun., 246, 470, 10.1006/bbrc.1998.8628

Steingrimsdottir, 2000, Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy, Antimicrob. Agents Chemother., 44, 207, 10.1128/AAC.44.1.207-209.2000

Weller, 1993, Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers, Clin. Pharmacol. Ther., 54, 595, 10.1038/clpt.1993.196

Eriksson, 2005, HPEPT1 affinity and translocation of selected Gln-Sar and Glu-Sar dipeptide derivatives, Mol. Pharm., 2, 242, 10.1021/mp050015+

Li, 1998, Structure–affinity relationships of Val-Val and Val-Val-Val stereoisomers with the apical oligopeptide transporter in human intestinal Caco-2 cells, J. Drug Target., 5, 317, 10.3109/10611869808997860

Tamura, 1996, Metabolism, uptake, and transepithelial transport of the diastereomers of Val-Val in the human intestinal cell line, Caco-2, Pharm. Res., 13, 1213, 10.1023/A:1016068421243

Vabeno, 2004, Phe-Gly dipeptidomimetics designed for the di-/tripeptide transporters PEPT1 and PEPT2: synthesis and biological investigations, J. Med. Chem., 47, 1060, 10.1021/jm031022+

Lorenzi, 2005, Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-d-ribofuranosyl)benzimidazole enhance metabolic stability in vitro and in vivo, J. Pharmacol. Exp. Therap., 314, 883, 10.1124/jpet.104.082412

Cao, 2012, Advances in research of PepT1-targeted prodrug, Asian J. Pharm. Sci., 7, 110

Tsume, 2012, The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzyme, Molecules, 17, 3672, 10.3390/molecules17043672

Woodman, 1980, Specificity of pyrimidine nucleoside phosphorylases and the phosphorolysis of 5-fluoro-2′-deoxyuridine, Cancer Res., 40, 507

Landowski, 2006, Nucleoside ester prodrug substrate specificity of liver carboxylesterase, J. Pharmacol. Exp. Therap., 316, 572, 10.1124/jpet.105.092726

Thông tin
Thông tin xuất bản

European Journal of Pharmaceutics and Biopharmaceutics

Tập 86

514-523

Thông tin tác giả